Are combination therapies the answer to battling KRAS cancers?
Dr Ulrich Dünzinger and Kristie Fernamberg talk about their work with the SOS1 KRAS inhibitor to block tumour-triggering signal
Search
Breakthrough-Therapy-Designation-Progressive-Fibrosing-ILD
FDA Grants nintedanib Breakthrough Therapy Designation for Chronic Fibrosing ILDs with a Progressive Phenotype
Moving to Germany
We started in Germany, but we have offices all over the world.
BI 764532
DLL3/CD3 T-cell engager
BI 764532
DLL3/CD3 T-cell engager
BI 764532
DLL3/CD3 T-cell engager: DLL3/CD3 T-cell engager
Respimat media
DLL3/CD3 T-cell engager
DLL3/CD3 T-cell engager
Our core product areas
Our core product areas
Our core product areas
From social worker to joining the pharmaceutical industry
Patient centricity: How Miyuki Ono contributes to our diverse workforce with her experience as a social worker and helps patients in Japan
Connect with your heart
If you know someone who has #type2diabetes, they are twice as likely to develop heart failure than those without.
CD137/FAP agonist
CD137/FAP agonist
Phase II trials for patients with bronchiectasis
Bronchiectasis is a chronically progressive pulmonary disease. Boehringer Ingelheim investigates a potential new treatment option in two Phase II trials.
InSensitive Content: the impact on dermatologists
Learn about the importance of the dermatology community sharing content related to generalized pustular psoriasis on social media.
B7-H6/CD3 T-Cell Engager
B7-H6/CD3 T-Cell Engager
KISIMA® cancer vaccine
KISIMA® Cancer Vaccine
VSV-GP
VSV-GP
Quality
At Boehringer Ingelheim, Quality is deeply embedded into the lifecycle of the product: from Research and development to the delivery to our patients.
Kobe
The Kobe Pharma Research Institute takes part in the global research and development activities for human pharmaceuticals.
Facts about the INPULSIS™ trials
EMPRISE
Learn about the EMPRISE real-world evidence study and use of empagliflozin in routine clinical care
Our Expectations
We expect adherence to exemplary ethical and professional conduct both within the company and from our business partners.
Powered By Our People – A Global IT Community
With state-of-the-art digital tranformation and almost 2,000 colleagues working in IT at our locations across the world, we have powered the unprecedented growth of our global IT team – the people behind our pioneering information technology progress
Expertise in microbial | Bioxcellence | Boehringer Ingelheim
Leverage BioXcellence's expertise in microbial production, providing high-quality, reliable biopharmaceutical manufacturing solutions for your business.